Cargando…

Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents

BACKGROUND: Moraxella catarrhalis is a commensal organism of the respiratory tract that has emerged as an important pathogen for a variety of upper and lower respiratory tract infections including otitis media and acute exacerbations of chronic bronchitis. Susceptibility testing of M catarrhalis is...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandet, Tamara, Whitehead, Sue, Blondel-Hill, Edith, Wagner, Ken, Cheeptham, Naowarat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pulsus Group Inc 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173978/
https://www.ncbi.nlm.nih.gov/pubmed/25285112
_version_ 1782336279026860032
author Bandet, Tamara
Whitehead, Sue
Blondel-Hill, Edith
Wagner, Ken
Cheeptham, Naowarat
author_facet Bandet, Tamara
Whitehead, Sue
Blondel-Hill, Edith
Wagner, Ken
Cheeptham, Naowarat
author_sort Bandet, Tamara
collection PubMed
description BACKGROUND: Moraxella catarrhalis is a commensal organism of the respiratory tract that has emerged as an important pathogen for a variety of upper and lower respiratory tract infections including otitis media and acute exacerbations of chronic bronchitis. Susceptibility testing of M catarrhalis is not routinely performed in most diagnostic laboratories; rather, a comment predicting susceptibility based on the literature is attached to the report. The most recent Canadian report on M catarrhalis antimicrobial susceptibility was published in 2003; therefore, a new study at this time was of interest and importance. OBJECTIVE: To determine the susceptibility of M catarrhalis isolates from British Columbia to amoxicillin-clavulanate, doxycycline, clarithromycin, cefuroxime, levofloxacin and trimethoprimsulfamethoxazole. METHODS: A total of 117 clinical M catarrhalis isolates were isolated and tested from five Interior hospitals and two private laboratory centres in British Columbia between January and December 2012. Antibiotic susceptibility of M catarrhalis isolates was characterized using the Etest (E-strip; bioMérieux, USA) according to Clinical Laboratory Standards Institute guidelines. RESULTS: All isolates were sensitive to amoxicillin-clavulanate, doxycycline, clarithromycin, levofloxacin and trimethoprimsulfamethoxazole. One isolate was intermediately resistant to cefuroxime, representing a 99.15% sensitivity rate to the cephem agent. Cefuroxime minimum inhibitory concentrations (MICs) inhibiting 50% and 90% of organisms (MIC50 and MIC90) were highest among the antibiotics tested, and the MIC90 (3 μg/mL) of cefuroxime reached the Clinical Laboratory Standards Institute breakpoint of susceptibility. DISCUSSION: The antibiotic susceptibility of M catarrhalis isolates evaluated in the present study largely confirms the findings of previous surveillance studies performed in Canada. Cefuroxime MICs are in the high end of the sensitive range and the MIC50 and MIC90 observed in the present study are the highest ever reported in Canada. CONCLUSION: Although cefuroxime MICs in M catarrhalis are high, all agents tested showed antimicrobial activity, supporting their continued therapeutic and empirical use.
format Online
Article
Text
id pubmed-4173978
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Pulsus Group Inc
record_format MEDLINE/PubMed
spelling pubmed-41739782014-10-03 Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents Bandet, Tamara Whitehead, Sue Blondel-Hill, Edith Wagner, Ken Cheeptham, Naowarat Can J Infect Dis Med Microbiol Original Article BACKGROUND: Moraxella catarrhalis is a commensal organism of the respiratory tract that has emerged as an important pathogen for a variety of upper and lower respiratory tract infections including otitis media and acute exacerbations of chronic bronchitis. Susceptibility testing of M catarrhalis is not routinely performed in most diagnostic laboratories; rather, a comment predicting susceptibility based on the literature is attached to the report. The most recent Canadian report on M catarrhalis antimicrobial susceptibility was published in 2003; therefore, a new study at this time was of interest and importance. OBJECTIVE: To determine the susceptibility of M catarrhalis isolates from British Columbia to amoxicillin-clavulanate, doxycycline, clarithromycin, cefuroxime, levofloxacin and trimethoprimsulfamethoxazole. METHODS: A total of 117 clinical M catarrhalis isolates were isolated and tested from five Interior hospitals and two private laboratory centres in British Columbia between January and December 2012. Antibiotic susceptibility of M catarrhalis isolates was characterized using the Etest (E-strip; bioMérieux, USA) according to Clinical Laboratory Standards Institute guidelines. RESULTS: All isolates were sensitive to amoxicillin-clavulanate, doxycycline, clarithromycin, levofloxacin and trimethoprimsulfamethoxazole. One isolate was intermediately resistant to cefuroxime, representing a 99.15% sensitivity rate to the cephem agent. Cefuroxime minimum inhibitory concentrations (MICs) inhibiting 50% and 90% of organisms (MIC50 and MIC90) were highest among the antibiotics tested, and the MIC90 (3 μg/mL) of cefuroxime reached the Clinical Laboratory Standards Institute breakpoint of susceptibility. DISCUSSION: The antibiotic susceptibility of M catarrhalis isolates evaluated in the present study largely confirms the findings of previous surveillance studies performed in Canada. Cefuroxime MICs are in the high end of the sensitive range and the MIC50 and MIC90 observed in the present study are the highest ever reported in Canada. CONCLUSION: Although cefuroxime MICs in M catarrhalis are high, all agents tested showed antimicrobial activity, supporting their continued therapeutic and empirical use. Pulsus Group Inc 2014 /pmc/articles/PMC4173978/ /pubmed/25285112 Text en Copyright© 2014 Pulsus Group Inc. All rights reserved This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact support@pulsus.com
spellingShingle Original Article
Bandet, Tamara
Whitehead, Sue
Blondel-Hill, Edith
Wagner, Ken
Cheeptham, Naowarat
Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents
title Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents
title_full Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents
title_fullStr Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents
title_full_unstemmed Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents
title_short Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents
title_sort susceptibility of clinical moraxella catarrhalis isolates in british columbia to six empirically prescribed antibiotic agents
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173978/
https://www.ncbi.nlm.nih.gov/pubmed/25285112
work_keys_str_mv AT bandettamara susceptibilityofclinicalmoraxellacatarrhalisisolatesinbritishcolumbiatosixempiricallyprescribedantibioticagents
AT whiteheadsue susceptibilityofclinicalmoraxellacatarrhalisisolatesinbritishcolumbiatosixempiricallyprescribedantibioticagents
AT blondelhilledith susceptibilityofclinicalmoraxellacatarrhalisisolatesinbritishcolumbiatosixempiricallyprescribedantibioticagents
AT wagnerken susceptibilityofclinicalmoraxellacatarrhalisisolatesinbritishcolumbiatosixempiricallyprescribedantibioticagents
AT cheepthamnaowarat susceptibilityofclinicalmoraxellacatarrhalisisolatesinbritishcolumbiatosixempiricallyprescribedantibioticagents